Hepta Medical

Executive Summary

Hepta Medical is a French medtech company developing a pioneering microwave ablation platform that integrates an in-situ tissue temperature sensor with proprietary predictive software for real-time monitoring of ablation procedures. Founded in 2017 and based in Paris, the company addresses critical limitations in current tumor ablation techniques, such as lack of real-time feedback and inconsistent treatment zones. The platform enables clinicians to precisely control and adjust the ablation process, potentially improving outcomes in liver, lung, and other solid tumor treatments while reducing recurrence rates and collateral damage. By combining microwave energy with dynamic temperature sensing and predictive modeling, Hepta aims to enhance the safety and efficacy of minimally invasive cancer therapies.

Upcoming Catalysts (preview)

• Q3 2026CE Mark Approval for Microwave Ablation Platform70% success
• Q1 2027FDA 510(k) Submission for US Market Entry50% success
• Q2 2026Clinical Study Results Showing Improved Tumor Clearance Rates60% success